Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of HEC585 and Pirfenidone/Nintedanib in Healthy Subjects
NCT07588646Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of yifenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Area under the curve from 0 to 24 hours and Maximum Plasma Concentration at Day 36. Started Jun 2021; status: completed.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07588646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588646.